KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

Off #MRK, ASCO, Corporate News, Health, Health Information, Human Health, Latest News, Life Sciences, Medicine, Merck, Merck Pharmaceutical, NYSE:MRK, Oncology, Oncology Newsroom, Pharmaceuticals, Research and Development News, Science and Health, Science and Research

Dateline City:
KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.

Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.

Language:
English

Contact:

Merck Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Merck Investor Relations
Peter Dannenbaum: (908) 740-1037
Courtney Ronaldo: (908) 740-6132

Eisai Inc. Media Relations
Michele Randazzo: (551) 579-4465

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma »

About The Author